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Abstract
Research into the prevalence and impact of low-value medical practices has evolved substantially over the past two
decades. However, despite international efforts, many challenges still remain with regards to progress in this field,
including limits in the capacity to identify and prioritize low-value care practices and to systematically appraise
clinical and policy attempts at redressing low-value care. A recent article by Niven et al. in BMC Medicine consolidates
the current literature and terminology on the de-adoption of clinical practices, advocating the use of de-adoption as
an appropriate term to label low-value care and proposes a new synthesis model to facilitate efforts to reverse
ineffective and harmful medical practices. We hope that this work will facilitate advances in low-value care research
and policy, and shift focus towards establishing evidence for de-adopting low-value interventions, which is crucial since
attempts to reduce low-value care interventions have shown mixed results.
Please see related article: http://www.biomedcentral.com/1741-7015/13/255
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Background
In the 1990s, England’s National Institute for Health and
Care Excellence co-opted the term ‘disinvestment’ from
industry parlance, heralding its transition to the health
sector [1]. Within industrial settings, disinvestment pri-
marily refers to the removal of resources from obsolete
items such as machinery. In healthcare settings, there is
less scope for such binary verdicts and, as such, more at-
tention is given to the complex issues associated with
the ethics of waste reduction. The most common defin-
ition places it as “processes of withdrawing (partially or
completely) health resources from any existing health
care practices, procedures, technologies or pharmaceuti-
cals that are deemed to deliver little or no health gain
for their cost, and are thus not efficient health resource
allocations” [2], allowing for resource re-allocation. As
Niven et al. [3] so aptly indicate, many related concepts
are subsumed within misuse, overtreatment, overdiagno-
sis, overmedicalization, waste, opportunity cost, allocative
and/or technical efficiency, resource re-allocation, and
de-adoption. Terminological proliferation has ensued
for several years, as visualized in the word cloud presented
herein (Fig. 1) and derived from the most common terms
identified by Niven et al. [3].
The article by Niven et al. [3] represents an important
contribution to the field, representing, along with the
manuscripts referenced within it, a valuable repository
cataloguing the current state-of-the-science from around
the world with regards to efforts at reducing the use of
low-value healthcare. Throughout article we are reminded
that contemporary de-adoption initiatives can be likened
to ‘old wine in a new bottle’, for related programs have
emerged and re-emerged since the 1970s [4, 5]. While the
desire to minimize waste and deliver safe, effective, and ef-
ficient healthcare is old wine, the new bottle is represented
by ever-evolving research, analysis, health technology as-
sessment methods, and dovetailed policy processes. It is
clear that the clinical, research, and policy communities
have attended to the successes and failures of the past and
are evolving to develop more robust methods moving for-
ward. Further, many of the challenges faced are universal
(e.g. sources of resistance to a potential loss function, bur-
den of evidence requirements, levers to encourage optimal
use), yet initiatives tend to be context specific: there is no* Correspondence: danijela.gnjidic@sydney.edu.au
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one-size-fits-all approach and, for numerous evolving pro-
grams, their success remains uncertain.
Nevertheless, despite increasing international efforts,
researchers are still faced with significant challenges with
regards to research on low-value clinical practices [6].
Curiously, the ability to identify and prioritize which
practices are of low-value appears to have overtaken the
ability to systematically evaluate the clinical and policy
attempts at reducing low-value care [7]. Indeed, strat-
egies such as Choosing Wisely have been established in
the USA, UK, Canada and, recently, Australia to identify
and (it is to be assumed) reduce the overuse of inter-
ventions considered as low-value. To illustrate some
examples of low-value interventions we present the
International Choosing Wisely Top 10 list [8].
 Imaging for low back pain
 Stress cardiac imaging for initial evaluation
 Annual stress cardiac imaging
 Pre-op testing before low risk surgery
 Antibiotics for sinusitis
 Benzodiazepines in the elderly
 Long-term proton-pump inhibitor therapy for
gastrointestinal symptoms
 Antipsychotics for dementia
 Antimicrobials for bacteriuria in elderly
 Urinary catheters
For instance, overuse of pharmaceutical agents of ques-
tionable benefit, such as antipsychotics among people with
dementia, has been of particular concern. Despite strong
evidence that antipsychotic use is linked with significant
harms and that the cessation or deprescribing of anti-
psychotics is safe, these agents continue to be overused
among people with dementia [9]. Efforts are needed to
establish evidence-based guidelines for the most effect-
ive interventions to deprescribe antipsychotics and
other medications of questionable benefit in this patient
group [10, 11].
Given this background, Niven et al.’s scoping review
[3] consolidates the current literature and terminology
on the de-adoption of clinical practices, with the ultim-
ate aim to develop a new synthesis model for providers
and decision-makers to facilitate the reversal of ineffect-
ive and harmful medical practices. The authors identified
43 different terms used to refer to the process of de-
adoption, with ‘disinvest’ (39 %) and ‘decrease use’ (24 %)
being the most frequently cited terms. They further rec-
ommend that ‘de-adoption’ should be the term used to
standardize the literature on low-value clinical care. Given
the increasing focus on generating evidence to inform
low-value care practices, we agree that reaching a con-
sensus on the most appropriate term to be used to refer
to low-value care is of benefit. We recommend that re-
searchers debate the use of the ‘de-adoption’ term to
standardize the terminology [6]. Interestingly, de-adopt
was only cited by 3 % of the included papers. It remains
to be seen whether this will impose some barriers to imple-
menting the ‘de-adoption’ term in the relevant literature.
Niven et al. [3] also indicate that the most prominent
low-value care ‘red flag’ in their sourced studies was that
of safety concerns. While legitimate, the onus is on clini-
cians and researchers to conduct further studies to gen-
erate evidence about low-value practices based on their
ineffectiveness rather than the red flag of safety alone.
To further progress the field, the authors propose a de-
adoption framework model based on 13 frameworks that
conceptualize individual components of a de-adoption
process. The question is, how can attention be focused
towards the implementation of this framework to guide
the de-adoption of ineffective and harmful practices? Each
framework component must be considered to understand
the issues that underpin this model and be able to answer
the question above.
Untangling the de-adoption framework
Historically, the primary focus lay on identifying low-
value clinical practices; focus has now shifted to prioritiz-
ing selected low-value practices for evidence-based review
or reassessment [7, 12]. The assessment or measurement
of the prevalence of low-value practices has recently re-
ceived significant attention. While these methods are
evolving, there remains a need for considerable further
measurement worldwide [6]. Additionally, the design and
implementation of de-adoption initiatives at the clinical
and policy levels is no simple task. Arguably, there is no
Fig. 1 Word cloud of frequency of terms used to label low-value care
practices and policy processes, derived by entering the 43 terms
identified by Nieven et al. [3] in nVivo software
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one model to drive this step given that the circumstances
of individual healthcare environments are widely varied
and context specific [13]. For example, as the recent
OECD report reveals [14], individual countries have tack-
led the problem of cesarean delivery over-use differently,
all with varying degrees of success. Niven et al. [3] further
emphasize this point in their synthesis. So too, rather than
re-inventing the wheel, the ‘adaptation of a knowledge
step’ in the Niven model is well founded, with growing ex-
amples of existing policy processes that can be merged
with promising initiatives, thus adding value to the overall
process. The next step in their model involves the evalu-
ation of de-adoption processes and outcomes [15]. With-
out doubt, there is a dearth of information in this domain
due to the lack of a publication imperative by policy stake-
holders performing this work and/or due to evidence lying
in grey literature that is difficult to obtain. Sustaining de-
adoption initiatives is particularly challenging and it is well
regarded in the field that de-adoption is far from merely
reversing the implementation process [6]. The last step of
this framework, namely the assessment of barriers and fa-
cilitators to the de-adoption of interventions, is perhaps
the most important. While this framework step has re-
ceived a great deal of attention from both the clinical and
policy analysis perspectives [2, 16, 17], it remains under-
represented in terms on quantitative evaluation.
Conclusions
We commend the authors for summarizing the current
literature on low-value clinical practices, the terminology
used thus far, and the impact of de-adoption interventions.
This scoping review substantially contributes to the con-
tinuing maturation of low-value clinical practice literature.
This is an important step in consolidating the research to
date, particularly regarding what constitutes low-value
care, and is essential to generate the evidence base for
de-adoption approaches of clinical practice.
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